Morphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neurites

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Masvekar, Ruturaj R ^a   El Hage, Nazira ^a   Hauser, Kurt F ^a   Knapp, Pamela E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GAG PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; MORPHINE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; SIGNAL PEPTIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVE FIBER GROWTH; NEURITE; NEUROTOXICITY; NONHUMAN; U937 CELL LINE; ANIMAL; CELL DEATH; CYTOLOGY; DRUG EFFECTS; GLIA; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TUMOR CELL LINE; VIROLOGY; VIRUS LOAD;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CYTOKINES; GLYCOGEN SYNTHASE KINASE 3; HIV-1; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED ICR; MORPHINE; NEURITES; NEUROGLIA; SIGNAL TRANSDUCTION; VIRAL LOAD;

EID: 84903398771     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100196     Document Type: Article

References (88)

1. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, et al. (1992) Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736-1739.
2. Kramer-Hammerle S, Rothenaigner I, Wolff H, Bell JE, Brack-Werner R (2005) Cells of the central nervous system as targets and reservoirs of the human immunodeficiency virus. Virus Res 111: 194-213. (Pubitemid 40909736)
3. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000) Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 6 Suppl 1: S70-81. (Pubitemid 30342780)
4. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8: 33-44. (Pubitemid 46011997)
5. Epstein LG, Gendelman HE (1993) Human immunodeficiency virus type 1 infection of the nervous system: pathogenetic mechanisms. Ann Neurol 33: 429-436. (Pubitemid 23143022)
6. Garden GA (2002) Microglia in human immunodeficiency virus-associated neurodegeneration. Glia 40: 240-251.
7. Xiong H, Zeng YC, Lewis T, Zheng J, Persidsky Y, et al. (2000) HIV-1 infected mononuclear phagocyte secretory products affect neuronal physiology leading to cellular demise: relevance for HIV-1-associated dementia. J Neurovirol 6 Suppl 1: S14-23. (Pubitemid 30342773)
8. Cysique LA, Maruff P, Brew BJ (2004) Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 10: 350-357. (Pubitemid 40109622)
9. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ (2003) Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 1539-1545. (Pubitemid 36900555)
10. Cysique LA, Brew BJ (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19: 169-185.
11. Sacktor N (2002) The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol 8 Suppl 2: 115-121.
12. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, et al. (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21: 1915-1921. (Pubitemid 47329768)
13. Kerza-Kwiatecki AP, Amini S (1999) CNS as an HIV-1 reservoir; BBB and drug delivery. J Neurovirol 5: 113-114.
14. Robertson K, Liner J, Meeker RB (2012) Antiretroviral neurotoxicity. J Neurovirol 18: 388-399.
15. Johnson TP, Patel K, Johnson KR, Maric D, Calabresi PA, et al. (2013) Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A 110: 13588-13593.
16. Bokhari SM, Yao H, Bethel-Brown C, Fuwang P, Williams R, et al. (2009) Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 15: 219-228.
17. Robertson JR, Ronald PJ, Raab GM, Ross AJ, Parpia T (1994) Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ 309: 369-372.
18. Rogers TJ, Peterson PK (2003) Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24: 116-121. (Pubitemid 36263094)
19. Sheng WS, Hu S, Gekker G, Zhu S, Peterson PK, et al. (1997) Immunomodulatory role of opioids in the central nervous system. Arch Immunol Ther Exp (Warsz) 45: 359-366. (Pubitemid 28098862)
20. Fitting S, Xu R, Bull C, Buch SK, El-Hage N, et al. (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177: 1397-1410.
21. Gurwell JA, Nath A, Sun Q, Zhang J, Martin KM, et al. (2001) Synergistic neurotoxicity of opioids and human immunodeficiency virus-1 Tat protein in striatal neurons in vitro. Neuroscience 102: 555-563. (Pubitemid 32171876)
22. Hu S, Sheng WS, Lokensgard JR, Peterson PK (2005) Morphine potentiates HIV-1 gp120-induced neuronal apoptosis. J Infect Dis 191: 886-889. (Pubitemid 40349803)
23. Zou S, Fitting S, Hahn YK, Welch SP, El-Hage N, et al. (2011) Morphine potentiates neurodegenerative effects of HIV-1 Tat through actions at mu-opioid receptor-expressing glia. Brain 134: 3616-3631.
24. Podhaizer EM, Zou S, Fitting S, Samano KL, El-Hage N, et al. (2012) Morphine and gp120 Toxic Interactions in Striatal Neurons are Dependent on HIV-1 Strain. J Neuroimmune Pharmacol 7: 877-891.
25. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, et al. (2008) Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 56: 1414-1427.
26. El-Hage N, Gurwell JA, Singh IN, Knapp PE, Nath A, et al. (2005) Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50: 91-106. (Pubitemid 40695264)
27. Bell JE, Arango JC, Robertson R, Brettle RP, Leen C, et al. (2002) HIV and drug misuse in the Edinburgh cohort. J Acquir Immune Defic Syndr 31 Suppl 2: S35-42. (Pubitemid 35190557)
28. Martinez AJ, Sell M, Mitrovics T, Stoltenburg-Didinger G, Iglesias-Rozas JR, et al. (1995) The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract 191: 427-443.
29. Byrd DA, Fellows RP, Morgello S, Franklin D, Heaton RK, et al. (2011) Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr 58: 154-162.
30. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, et al. (2005) HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis 191: 890-898. (Pubitemid 40349804)
31. Soulie C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, et al. (2009) Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr 51: 60-64.
32. Cheng-Mayer C, Levy JA (1988) Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 23 Suppl: S58-61.
33. Sawynok J (1986) The therapeutic use of heroin: a review of the pharmacological literature. Can J Physiol Pharmacol 64: 1-6.
34. Peterson PK, Gekker G, Hu S, Cabral G, Lokensgard JR (2004) Cannabinoids and morphine differentially affect HIV-1 expression in CD4(+) lymphocyte and microglial cell cultures. J Neuroimmunol 147: 123-126. (Pubitemid 38114961)
35. Singh IN, Goody RJ, Dean C, Ahmad NM, Lutz SE, et al. (2004) Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J Neurovirol. 10: 141-151. (Pubitemid 38868152)
36. Sholl DA (1953) Dendritic organization in the neurons of the visual and motor cortices of the cat. J Anat 87: 387-406.
37. Ikeda H, Miyatake M, Koshikawa N, Ochiai K, Yamada K, et al. (2010) Morphine modulation of thrombospondin levels in astrocytes and its implications for neurite outgrowth and synapse formation. J Biol Chem 285: 38415-38427.
38. Miyatake M, Rubinstein TJ, McLennan GP, Belcheva MM, Coscia CJ (2009) Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways. J Neurochem 110: 662-674.
39. El-Hage N, Bruce-Keller AJ, Yakovleva T, Bazov I, Bakalkin G, et al. (2008) Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-kappaB trafficking and transcription. PLoS One 3: e4093.
40. Berridge MV, Tan AS (1993) Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch Biochem Biophys 303: 474-482. (Pubitemid 23199849)
41. Liu Y, Peterson DA, Kimura H, Schubert D (1997) Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem 69: 581-593. (Pubitemid 27327958)
42. van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731: 237-245.
43. Royal W, 3rd, Selnes OA, Concha M, Nance-Sproson TE, McArthur JC (1994) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia. Ann Neurol 36: 32-39. (Pubitemid 24205821)
44. Bellizzi MJ, Lu SM, Gelbard HA (2006) Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J Neuroimmune Pharmacol 1: 20-31. (Pubitemid 44257497)
45. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, et al. (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9: 209-217. (Pubitemid 29157710)
46. Kim HJ, Martemyanov KA, Thayer SA (2008) Human immunodeficiency virus protein Tat induces synapse loss via a reversible process that is distinct from cell death. J Neurosci 28: 12604-12613.
47. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, et al. (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42: 963-972. (Pubitemid 28008427)
48. Hauser KF, Hahn YK, Adjan VV, Zou S, Buch SK, et al. (2009) HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia 57: 194-206.
49. McMillian MK, Hong JS (1994) Regulation of preproenkephalin expression in astrocytes: is there a role for glia-derived opioid peptides in reactive gliosis? Crit Rev Neurobiol 9: 91-103.
50. Sargeant TJ, Miller JH, Day DJ (2008) Opioidergic regulation of astroglial/neuronal proliferation: where are we now? J Neurochem 107: 883-897.
51. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, et al. (2013) Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways. Nature.
52. Hatten ME, Lynch M, Rydel RE, Sanchez J, Joseph-Silverstein J, et al. (1988) In vitro neurite extension by granule neurons is dependent upon astroglial-derived fibroblast growth factor. Dev Biol 125: 280-289. (Pubitemid 18062466)
53. Le R, Esquenazi S (2002) Astrocytes mediate cerebral cortical neuronal axon and dendrite growth, in part, by release of fibroblast growth factor. Neurol Res 24: 81-92. (Pubitemid 34038400)
54. Rousselet A, Fetler L, Chamak B, Prochiantz A (1988) Rat mesencephalic neurons in culture exhibit different morphological traits in the presence of media conditioned on mesencephalic or striatal astroglia. Dev Biol 129: 495-504.
55. Crews L, Patrick C, Achim CL, Everall IP, Masliah E (2009) Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci 10: 1045-1063.
56. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, et al. (2003) Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 23: 9162-9170. (Pubitemid 37243817)
57. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, et al. (2005) Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25: 8375-8385. (Pubitemid 41324724)
58. Everall IP, Bell C, Mallory M, Langford D, Adame A, et al. (2002) Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 21: 493-501. (Pubitemid 36062734)
59. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S (1999) HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem 73: 578-586. (Pubitemid 29339830)
60. Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, et al. (2006) Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci 23: 2623-2634. (Pubitemid 43801454)
61. Anthony IC, Norrby KE, Dingwall T, Carnie FW, Millar T, et al. (2010) Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers. Brain 133: 3685-3698.
62. Ramage SN, Anthony IC, Carnie FW, Busuttil A, Robertson R, et al. (2005) Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. Neuropathol Appl Neurobiol 31: 439-448. (Pubitemid 41059865)
63. Frame S, Cohen P, Biondi RM (2001) A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 7: 1321-1327. (Pubitemid 32607364)
64. Jacobs KM, Bhave SR, Ferraro DJ, Jaboin JJ, Hallahan DE, et al. (2012) GSK-3beta: A Bifunctional Role in Cell Death Pathways. Int J Cell Biol 2012: 930710.
65. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65: 391-426. (Pubitemid 32781670)
66. Kaytor MD, Orr HT (2002) The GSK3 beta signaling cascade and neurodegenerative disease. Curr Opin Neurobiol 12: 275-278. (Pubitemid 34615752)
67. Kumar R, Orsoni S, Norman L, Verma AS, Tirado G, et al. (2006) Chronic morphine exposure causes pronounced virus replication in cerebral compartment and accelerated onset of AIDS in SIV/SHIV-infected Indian rhesus macaques. Virology 354: 192-206. (Pubitemid 44441512)
68. Bokhari SM, Hegde R, Callen S, Yao H, Adany I, et al. (2011) Morphine potentiates neuropathogenesis of SIV infection in rhesus macaques. J Neuroimmune Pharmacol 6: 626-639.
69. Reid W, Sadowska M, Denaro F, Rao S, Foulke J, Jr., et al. (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98: 9271-9276. (Pubitemid 32743906)
70. Shacklett BL (2008) Can the new humanized mouse model give HIV research a boost. PLoS Med 5: e13.
71. Singh IN, El-Hage N, Campbell ME, Lutz SE, Knapp PE, et al. (2005) Differential involvement of p38 and JNK MAP kinases in HIV-1 Tat and gp120-induced apoptosis and neurite degeneration in striatal neurons. Neuroscience 135: 781-790. (Pubitemid 41407741)
72. Suzuki M, El-Hage N, Zou S, Hahn YK, Sorrell ME, et al. (2011) Fractalkine/CX3CL1 protects striatal neurons from synergistic morphine and HIV-1 Tat-induced dendritic losses and death. Mol Neurodegener 6: 78-95.
73. Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, et al. (1995) Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 15: 3328-3341.
74. Berger JR, Nath A (1997) HIV dementia and the basal ganglia. Intervirology 40: 122-131. (Pubitemid 28021606)
75. Pang X, Panee J, Liu X, Berry MJ, Chang SL, et al. (2013) Regional Variations of Antioxidant Capacity and Oxidative Stress Responses in HIV-1 Transgenic Rats With and Without Methamphetamine Administration. J Neuroimmune Pharmacol 8: 691-704.
76. Fitting S, Zou S, Chen W, Vo P, Hauser KF, et al. (2010) Regional heterogeneity and diversity in cytokine and chemokine production by astroglia: differential responses to HIV-1 Tat, gp120, and morphine revealed by multiplex analysis. J Proteome Res 9: 1795-1804.
77. Proudnikov D, Randesi M, Levran O, Crystal H, Dorn M, et al. (2012) Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. J Infect Dis 205: 1745-1756.
78. O'Brien SJ, Moore JP (2000) The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 177: 99-111.
79. Zimmerman PA, Buckler-White A, Alkhatib G, Spalding T, Kubofcik J, et al. (1997) Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 3: 23-36. (Pubitemid 27142522)
80. Gilman CP, Mattson MP (2002) Do apoptotic mechanisms regulate synaptic plasticity and growth-cone motility? Neuromolecular Med 2: 197-214. (Pubitemid 37012504)
81. Jones G, Zhu Y, Silva C, Tsutsui S, Pardo CA, et al. (2005) Peripheral nerve-derived HIV-1 is predominantly CCR5-dependent and causes neuronal degeneration and neuroinflammation. Virology 334: 178-193. (Pubitemid 40386952)
82. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, et al. (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett 325: 167-172. (Pubitemid 23186470)
83. Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, et al. (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87: 1333-1344. (Pubitemid 38020568)
84. Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, et al. (1992) Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule- associated protein tau. FEBS Lett 314: 315-321. (Pubitemid 23005680)
85. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR (1992) Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114: 147-162. (Pubitemid 23008367)
86. Hauser KF, El-Hage N, Stiene-Martin A, Maragos WF, Nath A, et al. (2007) HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem 100: 567-586. (Pubitemid 46095610)
87. Chao CC, Hu S, Shark KB, Sheng WS, Gekker G, et al. (1997) Activation of mu opioid receptors inhibits microglial cell chemotaxis. J Pharmacol Exp Ther 281: 998-1004. (Pubitemid 27203837)
88. Takayama N, Ueda H (2005) Morphine-induced chemotaxis and brain-derived neurotrophic factor expression in microglia. J Neurosci 25: 430-435. (Pubitemid 40105613)